Curium Pharma has announced the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co., a prominent player in nuclear medicine based in Istanbul, Turkey. This acquisition enhances Curium's capacity to manufacture Lutetium-177 (Lu-177), addressing the increasing global demand for this isotope and supporting the development of its Lu-177 drug candidates for prostate cancer and neuroendocrine tumors. The merger will also expand Curium’s PET footprint from 34 to 46 sites across Europe and the MENA region. Curium's CEO for International Markets expressed enthusiasm about the integration, emphasizing the expansion of capabilities and opportunities to enhance patient diagnostics and therapies.
Fri, 28 Mar 2025 06:01:16 GMT | GlobeNewswire